Ultralife (ULBI) Q1 2026 earnings review
Execution Failures Mask Record Demand
Ultralife's revenue reversed its growth trajectory, falling 6.5% YoY to $47.4M and plunging the company into a net loss of $0.5M. Management blamed Q1's poor performance on weather, power outages, and facility integration activities. However, the data reveals a deeper structural issue: gross margins have now compressed for four consecutive quarters, exposing the company's inability to effectively pass on tariff and utility costs. The sole bright spot is a record $115.1M backlog, proving that while underlying product demand remains robust, manufacturing execution is currently broken.
🐂 Bull Case
The backlog has accelerated to a record $115.1M, up from a trough of $89M in 25Q2. This indicates strong end-market demand for the company's long-cycle products, providing a clear path to revenue recovery if manufacturing bottlenecks are resolved.
Management quantified $1.66M in non-recurring items and production impacts (weather, power outage, integrations) that severely hit the Q1 bottom line. Absent these items, operating income would have been positive.
🐻 Bear Case
Gross margins decelerated to 21.3% from 25.1% a year ago. Management's 2025 narrative that tariff surcharges would protect profitability has proven false, as structural utility and supply chain costs outpace pricing power.
The high-margin Communications Systems segment fell another 25.7% YoY. Management promised a rebound in H2 2025, yet the segment continues to shrink, raising questions about its long-term viability.
⚖️ Verdict: 🔴
Bearish. A record backlog is useless if a company cannot manufacture products profitably. Four quarters of margin decay and a failure to deliver the promised Communications rebound suggest deep operational issues that overshadow strong demand.
Key Themes
Margin Contradiction: Weather vs. Structural Decay
Management heavily attributed the Q1 operating loss to 'inclement weather' and 'power outages.' However, the data directly contradicts the narrative that this is a sudden shock. Gross margins have been decelerating steadily: 25.1% (25Q1) -> 23.9% (25Q2) -> 22.2% (25Q3) -> 21.3% (26Q1). Tariffs and soaring utility costs are structurally impairing the business, and the company lacks the pricing power to offset them.
Backlog Hits Record High
Accelerating. The total order backlog exiting Q1 hit $115.1M, representing a 21% YoY increase and sequentially building on Q4 2025's $110.2M. This confirms that despite manufacturing chaos, the underlying demand for Ultralife's military and medical batteries remains intact. It is the single most important growth driver for late 2026.
Communications Rebound Narrative Fails
Throughout 2025 calls, management insisted the Communications segment would rebound as delayed orders materialized. Instead, the segment is reversing further, dropping 25.7% YoY to just $3.3M in 26Q1. With gross margins here also falling drastically from 29.5% to 22.8% due to lost volume leverage, this segment has shifted from a high-margin growth engine to a severe financial drag.
Macro Pressures: Tariffs and Utility Costs
Macro headwinds continue to batter the supply chain. Management explicitly cited 'product mix impacting tariffs' and 'significantly higher utility costs' as margin killers. The inability to seamlessly pass these costs to customers indicates rigid supply contracts or intense market competition.
Aggressive R&D Investments Unchanged
Despite the net loss, management is not cutting the future. R&D expenses accelerated 23.3% YoY to $3.0M. This ongoing investment in new technologies, specifically ruggedized amplifiers and conformal wearable batteries, is directly responsible for the record backlog and long-term pipeline.
Elevated One-Time Consulting and Litigation Costs
Operating expenses jumped to 21.8% of revenue, exacerbated by $0.8M in non-recurring consulting fees designed to 'expedite gross margin improvement' and litigation expenses for a cyber-insurance claim. The reliance on outside consultants to fix internal manufacturing inefficiencies is a red flag regarding current operational leadership.
Other KPIs
Decelerating aggressively. Adjusted EBITDA fell 40% YoY from $5.4M, with margins compressing to 6.8% from 10.7%. However, on a sequential basis, it shows a slight stabilization compared to the $2.0M trough seen in Q3 2025. TTM Adjusted EBITDA now sits at $15.0M.
Accelerating. SG&A and R&D jumped 10.5% YoY despite revenue falling 6.5%. This negative operating leverage was the primary driver pulling the company into an operating loss of $0.2M for the quarter.
Guidance
Stable narrative, but lacking numbers. Management completely avoided giving numerical guidance for FY26. They only stated a focus on improving manufacturing efficiency at the Newark facility to 'restore profitability' and generate 'incremental cash flow.' Without concrete targets, investors are flying blind on the timeline for margin recovery.
Key Questions
Margin Contradiction
Gross margins have declined for four consecutive quarters. How much of the Q1 compression was truly driven by the isolated power outage versus structural, long-term inflation in utility and tariff costs?
Consulting ROI
You recorded significant consulting costs in Q1 to 'expedite gross margin improvement.' What specific operational changes are these consultants implementing, and in which quarter will we see the financial ROI from this spend?
Communications Bottom
The Communications segment has seen massive YoY declines for multiple quarters, despite previous expectations of a rebound. Are these delayed orders definitively lost to competitors, or are they sitting fully intact within the $115M backlog?
Backlog Conversion
With the backlog at a record $115.1 million, what percentage of this is scheduled to ship within the next 12 months, and do you have the manufacturing capacity to execute it without incurring further efficiency penalties?